NCT00390416View on ClinicalTrials.gov

Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Stomach NeoplasmsEsophageal Neoplasms
Interventions
DRUG

Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin

Bevacizumab 10mg/kg day 1 IV over 30 minutes Docetaxel 40mg/m2 day 1 IV over 1 hour Leucovorin 400mg/m2 day 1 IV over 30 minutes Fluorouracil 400mg/m2 IVP day 1 Fluorouracil 1000mg/m2 IVCI x 48 hours Cisplatin 40mg/m2 day 3 IV over 30 minutes

Trial Locations (5)

10021

Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York

11570

Memorial Sloan-Kettering Cancer Center at Mercy Medical Center, Rockville Centre

11725

Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack

Unknown

Memoral Sloan Kettering Cancer Center, Basking Ridge

Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital, Sleepy Hollow

Sponsors

Collaborators (2)

Sanofi
Genentech, Inc.
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER